Basking In Phase III Telaprevir Success, Vertex Maps Hepatitis C Market

After releasing glowing topline Phase III results for telaprevir, Vertex took pains to reassure investors that it is up to the commercial job of competing against Big Pharma and that it has done its homework on the developing hepatitis C market